Best Practices and Future Directions for Bispecific Antibody Therapy

This final segment highlights practical lessons learned from implementing bispecific antibody therapies and explores how the field may evolve in the coming years. Panelists emphasize that optimizing outcomes requires multidisciplinary collaboration, standardized protocols, and continuous education across clinical teams. Dedicated infectious disease support, particularly for patients receiving cellular or T-cell–redirecting therapies, can improve management of infection risks and other delayed complications.

Operational success also depends on well-coordinated transitions of care between infusion centers, inpatient teams, and community oncologists. Establishing treatment pathways in advance, including scheduled laboratory testing, infusion appointments, observation periods, and follow-up visits, helps ensure seamless care delivery and improves patient confidence in the treatment process. Practical tools such as patient calendars outlining medications and monitoring schedules can also reduce confusion and improve adherence.

Looking ahead, panelists anticipate that bispecific antibodies will continue to expand beyond their current use in later-line therapy for relapsed/refractory diffuse large B-cell lymphoma. Ongoing clinical trials are evaluating combination strategies with chemotherapy, antibody-drug conjugates, and other immunotherapies, as well as their potential use in earlier lines of treatment, including the frontline setting. As evidence accumulates, these therapies are expected to play an increasingly central role in lymphoma management.